Podcast Episodes
Back to Search
Ep. 306 - Treg Inflection Point; Biotech's Next Big Story; Tax Bill Consequences
Season 6 Episode 306
Treg-based cell therapies are nearing a clinical proof-of-concept inflection point, but in an environment that has dramatically shifted with the adve…
1 year, 2 months ago
Ep. 305 - FDA's Future; In Vivo CAR T Plays; Psychedelics; CDK2
Season 6 Episode 305
The Trump administration’s overhaul of FDA is still underway, but the agency has already veered away from its decades-long trajectory in ways that wi…
1 year, 2 months ago
Ep. 304 - Syncona Reshapes Fund; Lilly's $1B Verve Bet; FDA's 2-Track Future
Season 6 Episode 304
Publicly traded U.K. investment firm and company builder Syncona is restructuring its fund amid ongoing market challenges in the biopharma industry. …
1 year, 2 months ago
Ep. 303 - Gene Therapy Safety, Amylin in Obesity & FDA's Future
Season 6 Episode 303
The tragic death of a second non-ambulatory DMD patient treated with Sarepta's Elevidys gene therapy marks a turning point for the field and should d…
1 year, 2 months ago
Ep. 302 - Takeaways from BioCentury Grand Rounds Chicago
Season 6 Episode 302
With federal funding at risk and VCs increasingly focused on de-risked assets, academia is facing unprecedented headwinds despite rapid advancements …
1 year, 2 months ago
Ep. 301 - ASCO’s First-in-Human Trials, Crossover Investors & FDA's Rare Disease Plans
Season 6 Episode 301
Translational trends at this year’s ASCO meeting featured new and selective ways to target cell surface receptors on solid tumors. On the latest BioC…
1 year, 2 months ago
Ep. 300 - Biotech’s $13B Deal Day, ASCO's Hot Targets, Drug Pricing Threat
Season 6 Episode 300
Dealmaking by a pair of pharmas has given the biotech industry its best day of transactions in months, tallying nearly $13 billion in guaranteed paym…
1 year, 3 months ago
Ep. 299 - ASCO, EpCAM, Rocket & HK IPOs
Season 6 Episode 299
Dutch biotech Merus’ EGFR x LGR5 bispecific antibody has caught investors’ attention in the run-up to ASCO as a new approach to block EGFR signaling.…
1 year, 3 months ago
Ep. 298 - Takeaways from the 25th Bio€quity Europe
Season 6 Episode 298
Political and market turmoil has raised questions whether the U.S. can retain its biopharma leadership position, and in turn presents Europe with an …
1 year, 3 months ago
Ep. 297 - European Biotech's Moment? Plus: Biomarin, Boston Deals & Novo Nordisk CEO
Season 6 Episode 297
The turbulence that has come with the Trump administration’s policies related to the U.S. biopharmaceutical industry is creating an opening for Europ…
1 year, 3 months ago